Breakthrough in COPD Treatment: Tezspire shows promise in mid-stage data Breakthrough in COPD Treatment: Tezspire shows promise in mid-stage data

Photo of author

By Ronald Tech

Elderly Man Using Nebulizer
  • The recent release of phase 2a data on Tezspire, the asthma biologic developed by AstraZeneca (NASDAQ:AZN) and Amgen (NASDAQ:AMGN), brings a ray of hope for patients battling chronic obstructive pulmonary disease (COPD).
  • Results from the COURSE trial, while not statistically significant, suggest that patients treated with Tezspire experienced a 17% decrease in the annual rate of moderate or severe COPD exacerbations when compared to those on a placebo over a year.
  • Furthermore, for patients with blood eosinophil counts equal to or greater than 150 cells/µL, tezepelumab led to a “nominally significant” 37% reduction in the rate of exacerbations compared to the placebo.


See also  Netflix To Feature 'Crossroads' Starring Britney Spears on Its Platform Netflix To Feature 'Crossroads' Starring Britney Spears on Its Platform